Raw Materials & Excipients Management – Page 24

Change control documentation gaps during supplier change – CAPA to prevent repeat failures

Addressing Gaps in Change Control Documentation During Supplier Transitions In the dynamic pharmaceutical landscape, managing supplier changes is critical for maintaining product quality and regulatory compliance. Frequently, organizations face challenges…

Critical supplier risk not assessed during supplier onboarding – evidence pack for vendor oversight

Recognizing the right signals is key to early detection of issues related to supplier onboarding. Symptoms may manifest as:Click to read the full article.

Change control documentation gaps during post-approval change review – regulatory expectations for material changes

Addressing Documentation Gaps in Change Control During Post-Approval Material Changes In the ever-evolving landscape of pharmaceutical manufacturing, change control is a critical process that ensures quality and compliance. However, as…

Inadequate vendor qualification during regulatory inspection – supplier risk classification strategy

The first step in addressing inadequate vendor qualification is to identify observable symptoms that signal a problem. These signals can arise from various sources including; unusual assay results, unexpected variations…

Change impact underestimated during deviation investigation – CAPA to prevent repeat failures

Identifying the symptoms and signals that indicate a potential change impact is crucial for early intervention. Key symptoms might include:Click to read the full article.

Supplier audit findings escalated during requalification – inspection questions regulators ask

Recognizing symptoms or signals early on is crucial for effective investigation. Symptoms of supplier audit findings may manifest through various indicators, including:Click to read the full article.

Supplier change not evaluated during supplier change – inspection questions regulators ask

The first step in managing supplier changes is the identification of symptoms that may indicate a problem with the materials received from suppliers. Recognizing these signals early can prevent further…

Critical supplier risk not assessed during routine supplier audit – supplier risk classification strategy

Identifying symptoms early is crucial in preventing a full-blown quality crisis. Signs that critical supplier risks are present include:Click to read the full article.

Change impact underestimated during regulatory inspection – risk-based change impact assessment

The first step in recognizing the impact of changes in raw materials is identifying symptoms on the manufacturing floor or within the quality control laboratory. Some potential signals include:Click to…

Vendor change implemented without approval during routine supplier audit – supplier risk classification strategy

During the audit, several symptoms may become apparent indicating that a vendor change has been made without the mandated approval:Click to read the full article.

Supplier change not evaluated during regulatory inspection – regulatory expectations for material changes

Identifying the symptoms of a supplier change that hasn’t been evaluated can save a company significant time and resources. Here are some key indicators:Click to read the full article.

Sampling SOP not followed during internal audit – GMP expectations for material sampling

Investigating Non-Compliance with Internal Audit SOPs for Material Sampling In the realm of pharmaceutical manufacturing, adherence to standard operating procedures (SOPs) is non-negotiable, particularly during internal audits. A scenario that…